https://www.selleckchem.com/pr....oducts/gsk3368715.ht
To establish the utility of venous creatinine as a biomarker to monitor loss of fat-free mass in patients with amyotrophic lateral sclerosis (ALS). In this multicenter natural history study, body composition and venous creatinine were assessed in 107 patients with ALS and 52healthy controls. Longitudinal patterns of venous creatinine and its association with the risk of death during follow-up were determined in a cohort of patients with ALS from Australia (n=69) and the Netherlands (n=38). The mean levels of venous creatinine were 75